We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Catalyst Pharmaceutical (CPRX - Free Report) will report quarterly earnings of $0.64 per share in its upcoming release, pointing to a year-over-year decline of 5.9%. It is anticipated that revenues will amount to $147.08 million, exhibiting an increase of 4% compared to the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Catalyst metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Revenues- Product revenue, Net- FIRDAPSE' will reach $98.94 million. The estimate indicates a change of +18.2% from the prior-year quarter.
Analysts predict that the 'Revenues- Product revenue, Net- FYCOMPA' will reach $13.07 million. The estimate indicates a year-over-year change of -63.3%.
Analysts expect 'Revenues- Product revenue, Net- AGAMREE' to come in at $35.01 million. The estimate suggests a change of +58.8% year over year.
The average prediction of analysts places 'Revenues- Product revenue,net' at $147.01 million. The estimate indicates a change of +4% from the prior-year quarter.
Shares of Catalyst have demonstrated returns of +20.6% over the past month compared to the Zacks S&P 500 composite's +11.4% change. With a Zacks Rank #2 (Buy), CPRX is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts forecast that Catalyst Pharmaceutical (CPRX - Free Report) will report quarterly earnings of $0.64 per share in its upcoming release, pointing to a year-over-year decline of 5.9%. It is anticipated that revenues will amount to $147.08 million, exhibiting an increase of 4% compared to the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Catalyst metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Revenues- Product revenue, Net- FIRDAPSE' will reach $98.94 million. The estimate indicates a change of +18.2% from the prior-year quarter.
Analysts predict that the 'Revenues- Product revenue, Net- FYCOMPA' will reach $13.07 million. The estimate indicates a year-over-year change of -63.3%.
Analysts expect 'Revenues- Product revenue, Net- AGAMREE' to come in at $35.01 million. The estimate suggests a change of +58.8% year over year.
The average prediction of analysts places 'Revenues- Product revenue,net' at $147.01 million. The estimate indicates a change of +4% from the prior-year quarter.
View all Key Company Metrics for Catalyst here>>>Shares of Catalyst have demonstrated returns of +20.6% over the past month compared to the Zacks S&P 500 composite's +11.4% change. With a Zacks Rank #2 (Buy), CPRX is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .